Pulmonary Arterial Hypertension


Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.


Balloon Pulmonary Angioplasty: State of the Art


15 February 2021


Interventional Cardiology Review 2021;16:e02.

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator


European Cardiology Review 2018;13(1):35–7.

Atrial Arrhythmias in Pulmonary Hypertension


Arrhythmia & Electrophysiology Review 2018;7(1):43–8.

Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction


US Cardiology Review 2018;12(1):8–12.